The Role of Hydroxyurea on Growth in Children with SCD

The Role of Hydroxyurea on Growth in Children with SCD

Bibliographic Details
Main Author:	Zahrah Mohammed Alkashi
Format:	Article
Language:	English
Published:	Elsevier 2023-01-01
Series:	Journal of Taibah University Medical Sciences
Online Access:	http://www.sciencedirect.com/science/article/pii/S165836122300210X

Similar Items

Hydroxyurea utilization and dose optimization in children with sickle cell disease (SCD)
by: Nour Alotaibi, et al.
Published: (2023-01-01)

Effect of Low Dose of Hydroxyurea in SCD Children with Arab-Indian phenotype- Local Experience
by: Zahra Jaber Hussein
Published: (2023-01-01)

Outcome of Hydroxyurea Use in SCD and Evaluation of Patients’ Perception and Experience in Nigeria
by: Reuben Ikechukwu Chianumba, et al.
Published: (2022-03-01)

S269: MALE PATIENTS WITH SCD HAVE A HIGHER RISK OF CEREBROVASCULAR DISEASE, INCREASED INFLAMMATORY MARKERS, AND POORER RESPONSE TO HYDROXYUREA
by: Margherita DI Mauro, et al.
Published: (2023-08-01)

P-017: POINT-OF-CARE DIAGNOSTIC FOR QUANTIFICATION OF FOETAL HAEMOGLOBIN (HB F) LEVELS IN MONITORING HYDROXYUREA THERAPY FOR CHILDREN WITH SICKLE CELL DISEASE (SCD) IN GHANA
by: SEGBEFIA C., et al.
Published: (2022-08-01)

Is Hydroxyurea Treatment Changing the Life of Children with Sickle Cell Disease?
by: Mohammed Ali Al Sabbah, et al.
Published: (2023-07-01)

Role of Hydroxyurea in Patients of Beta Thalassemia Majo
by: Benish Fatima, et al.
Published: (2022-12-01)

P-042: POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS ANALYSIS OF HYDROXYUREA, IN ADULT PATIENTS WITH SICKLE CELL DISEASE (SCD) RECEIVING BOTH TABLETS OR CAPSULES FORMULATIONS, AND EVALUATION OF DISEASE MARKERS
by: BARTOLUCCI P., et al.
Published: (2022-08-01)

Hydroxyurea granules for the management of sickle cell disease in children
by: Grace Lovia Allotey-Babington, et al.
Published: (2022-07-01)

Hydroxyurea-induced melanonychia
by: Michael G. Buontempo, BS, et al.
Published: (2023-12-01)

Qualitative Analysis of Hydroxyurea
by: Stéfanno Souza Santos, et al.
Published: (2020-07-01)

Qualitative Analysis of Hydroxyurea
by: Stéfanno Souza Santos, et al.
Published: (2020-07-01)

Qualitative Analysis of Hydroxyurea
by: Stéfanno Souza Santos, et al.
Published: (2020-07-01)

Qualitative Analysis of Hydroxyurea
by: Stéfanno Souza Santos, et al.
Published: (2020-07-01)

Adherence to Hydroxyurea and Patients’ Perceptions of Sickle Cell Disease and Hydroxyurea: A Cross-Sectional Study
by: Mohammed Ali Madkhali, et al.
Published: (2024-01-01)

Sums of SCD sets and their applications to SCD operators and narrow operators
by: Kadets Vladimir, et al.
Published: (2010-02-01)

P-075: HYDROXYUREA: EFFECTS ON TREATMENT OF CHILDREN WITH HEMOGLOBINOPATHY SC
by: CAMPOS A., et al.
Published: (2022-08-01)

Hydroxyurea—The Good, the Bad and the Ugly
by: Marcelina W. Musiałek, et al.
Published: (2021-07-01)

Hydroxyurea-induced Tooth Discoloration
by: Muhammed Okuyucu, et al.
Published: (2020-02-01)

Blue Lunula Related with Hydroxyurea
by: Hava Üsküdar Teke, et al.
Published: (2013-03-01)

Evaluating the Roles of sCD14 and sCD14-ST in Diagnosing COPD and Predicting an Acute Exacerbation of COPD
by: Rui Zhang, et al.
Published: (2022-06-01)

sCD163, sCD28, sCD80, and sCTLA-4 as soluble marker candidates for detecting immunosenescence
by: Andrea Aprilia, et al.
Published: (2024-01-01)

Nitric Oxide Synthase Dependency in Hydroxyurea Inhibition of Erythroid Progenitor Growth
by: Tijana Subotički, et al.
Published: (2021-07-01)

THE ASSESSMENT OF CEREBROVASCULAR-DISEASE IN CHILDREN WITH SICKLE-CELL DISEASE (SCD)
by: Hewes, D, et al.
Published: (1993)

P1480: SPLENIC SEQUESTRATION IS MORE COMMON IN SCD-S/Β0-THAL THAN IN SCD-S/S PATIENTS: RESULTS FROM THE GERMAN SCD REGISTRY
by: P. Allard, et al.
Published: (2022-06-01)

Risk of classical Kaposi sarcoma by plasma levels of Epstein-Barr virus antibodies, sCD26, sCD23 and sCD30
by: Viviano Enza, et al.
Published: (2010-10-01)

Increased Serum Levels of sCD14 and sCD163 Indicate a Preponderant Role for Monocytes in COVID-19 Immunopathology
by: Jose Gómez-Rial, et al.
Published: (2020-09-01)

The Use of Hydroxyurea in the Treatment of COVID-19
by: Foster Melissa Robin Bowman, et al.
Published: (2021-10-01)

Oral lesions associated with hydroxyurea treatment
by: Regina Mendonça, et al.
Published: (2011-01-01)

The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea
by: Luiz Bernardino Lima da Silva, et al.
Published: (2012-01-01)

Influence of hydroxyurea on the course of germination and growth of rape (Brasica napus L.) seedlings
by: M. Kuraś, et al.
Published: (2015-01-01)

Elucidating the role of SCD1 in B cell development and function
by: Loo, Larry Sai Weng
Published: (2015)

Impact of hydroxyurea on clinical and biological parameters of sickle cell anemia in children in Abidjan
by: MIREILLE YAYO- AYE, et al.
Published: (2024-02-01)

Effect of Hydroxyurea Treatment on the Inflammatory Markers Among Children With Sickle Cell Disease
by: Asmaa M. Zahran MD, et al.
Published: (2020-01-01)

Moderate dose of hydroxyurea in children with sickle cell disease and stroke. Preliminary results
by: Sergio Machín-García, et al.

Nitric Oxide Mediation in Hydroxyurea and Nitric Oxide Metabolites’ Inhibition of Erythroid Progenitor Growth
by: Tijana Subotički, et al.
Published: (2021-10-01)

Minimal doses of hydroxyurea for sickle cell disease
by: C.S.P. Lima, et al.
Published: (1997-08-01)

Phases of crown-gall transformation susceptible to hydroxyurea
by: Aldona Rennert, et al.
Published: (2014-01-01)

Leg ulcer with long‐term hydroxyurea use
by: Mohammad Ammad Ud Din, et al.
Published: (2021-04-01)

PI-03: THE EFFECT OF HYDROXYUREA IN THE GUT MICROBIOME OF ANGOLAN CHILDREN WITH SICKLE CELL DISEASE
by: DELGADINHO M., et al.
Published: (2022-08-01)